{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-015635","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2023-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.841846+00:00","generated_at":"2026-06-10T19:50:51.870011+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Protalix appoints Eliot Richard Forster as Chairman; Zeev Bronfeld retires","bullets":["Forster appointed Chairman and independent director effective Sept 14, 2023; also joins Nominating Committee.","Zeev Bronfeld retires as Chairman after nearly three decades; cites recent drug approval as transition point.","Forster receives 10-year option for 85,715 shares vesting quarterly over 3 years and $70,000 annual fee.","Forster is non-executive chairman of Avacta Group and director of Immatics NV; former CEO of F-Star Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-015635","json":"https://secwatch.observer/filing/0001558370-23-015635.json","markdown":"https://secwatch.observer/filing/0001558370-23-015635.md","text":"https://secwatch.observer/filing/0001558370-23-015635.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023015635/0001558370-23-015635-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023015635/plx-20230912x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T19:50:51.870011+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d33bd45f3","claim":"Zeev Bronfeld retired as Chairman of the Board at Protalix BioTherapeutics, Inc..","evidence_excerpt":"Zeev Bronfeld, the Company’s current Chairman of the Board, has notified the Company of his retirement from the Company for personal reasons, effective as of the same date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023015635/0001558370-23-015635-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"ef65b3e86c","claim":"Eliot Richard Forster was appointed as Chairman of the Board at Protalix BioTherapeutics, Inc..","evidence_excerpt":"On September 12, 2023, Protalix BioTherapeutics, Inc. (the “Company”) announced the appointment by its Board of Directors of Eliot Richard Forster, Ph.D. as Chairman of the Company’s Board of Directors effective as of September 14, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023015635/0001558370-23-015635-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}